Baxter International Inc.
BAX
Rang in aandelen
#1695
Baxter International Inc., operating globally via its subsidiaries, is a... Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.
Aandeelprijs
$24.48
Marktkapitalisatie
$12.65B
Verandering (1 dag)
-2.20%
Verandering (1 jaar)
5.81%
Land
US
Handel Baxter International Inc. (BAX)
Categorie
Healthcare
P/E-ratio voor Baxter International Inc. (BAX)
P/E-ratio op October 2026 TTM: -12.16
Volgens de meest recente financiële rapporten en aandelenkoers van Baxter International Inc. is de huidige P/E-ratio (TTM) -12.16. Eind 2023 had het bedrijf een P/E van 7.37.
Historiek van P/E-ratio voor Baxter International Inc. van 2000 tot 2026
P/E-ratio aan het einde van elk jaar
| Jaar | P/E-verhouding | Wijzigen |
|---|---|---|
| 2026 (TTM) | -12.16 | -46.92% |
| 2024 | -22.91 | -411.12% |
| 2023 | 7.37 | -169.76% |
| 2022 | -10.56 | -131.46% |
| 2021 | 33.56 | -9.45% |
| 2020 | 37.06 | -12.84% |
| 2019 | 42.52 | 87.03% |
| 2018 | 22.73 | -61.01% |
| 2017 | 58.30 | 1,095.73% |
| 2016 | 4.88 | -77.30% |
| 2015 | 21.48 | 148.51% |
| 2014 | 8.64 | -15.23% |
| 2013 | 10.20 | 18.87% |
| 2012 | 8.58 | 24.73% |
| 2011 | 6.88 | -39.81% |
| 2010 | 11.43 | 30.20% |
| 2009 | 8.78 | -2.85% |
| 2008 | 9.03 | -24.08% |
| 2007 | 11.90 | 1.26% |
| 2006 | 11.75 | -11.68% |
| 2005 | 13.31 | -55.18% |
| 2004 | 29.69 | 170.37% |
| 2003 | 10.98 | 23.45% |
| 2002 | 8.89 | -65.50% |
| 2001 | 25.78 | 36.47% |
| 2000 | 18.89 | 0.00% |
P/E-ratio voor vergelijkbare bedrijven of concurrenten
| Bedrijf | P/E-ratio | Verschil in P/E-ratio | Land |
|---|---|---|---|
| 47.48 | -490.51% |
US
|
|
| 27.43 | -325.55% |
FR
|
|
| - | - |
JP
|
|
| 56.89 | -567.89% |
US
|
|
| - | - |
CH
|
Hoe lees je een P/E-ratio?
De koers-winstverhouding (P/E Ratio) meet de relatie tussen de aandelenprijs van een bedrijf en de winst per aandeel.
Een lage maar positieve P/E duidt op een bedrijf dat hoge winsten genereert ten opzichte van zijn huidige waardering en mogelijk ondergewaardeerd is. Een bedrijf met een hoge negatieve (dicht bij 0) P/E lijdt grote verliezen.
Bedrijven met een P/E boven 30 of een negatieve waarde worden meestal gezien als "groeiaandelen", wat betekent dat beleggers verwachten dat het bedrijf zal groeien of winstgevend zal worden.
Bedrijven met een positieve P/E onder de 10 worden meestal gezien als "waardeaandelen", wat betekent dat ze al zeer winstgevend zijn, maar weinig groei wordt verwacht.